Physicochemical characterization of five glyburide powders: A BCS based approach to predict oral absorption

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 69, Issue 3, 2008, Pages 1046-1056

  Wei, Hai ^a   Dalton, Chad ^c   Di Maso, Marie ^c   Kanfer, Isadore ^d   Löbenberg, Raimar ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d RHODES UNIVERSITY   (South Africa)

Author keywords

Advanced Compartmental Absorption and Transit model; Glyburide glibenclamide; Material characterization; Oral absorption; Particle size

Indexed keywords

GLIBENCLAMIDE; GLUKOVITAL; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; COMPUTER SIMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; PARTITION COEFFICIENT; PKA; POWDER; RAMAN SPECTROMETRY; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHYSICAL; COMPUTER SIMULATION; CRYSTALLIZATION; EXCIPIENTS; GLYBURIDE; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; POWDERS; SOLUBILITY; SPECTRUM ANALYSIS, RAMAN; SURFACE PROPERTIES; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 48349117242     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.01.026     Document Type: Article

References (32)

1. Pearson J.G. Pharmacokinetics of glyburide. Am. J. Med. 79 Suppl. 3B (1985) 67-71
2. Neuvonen P.J., and Kivisto K.T. The effects of magnesium hydroxide on the absorption and efficacy of two glibenclamide preparations. Br. J. Clin. Pharmacol. 32 (1991) 215-220
3. Davis S.N., and Granner D.K. Insulin, oral hypoglycemic agents and the pharmacology of endocrine pancreas. In: Gilman A.G. (Ed). The Pharmacological Basis of Therapeutics. ninth ed. (1996), McGraw-Hill, New York 1487-1518
4. Löbenberg .R., Krämer J., Shah V.P., Amidon G.L., and Dressman J.B. Dissolution testing as prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm. Res. 17 4 (2000) 439-444
5. Vogelpoel H., Welink J., Amidon G.L., Junginger H.E., Midha K.K., Möller H., Olling M., Shah V.P., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride and atenolol (Commentary). J. Pharm. Sci. 93 8 (2004) 1945-1956
6. Löbenberg R., and Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50 (2000) 3-12
7. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 5 (1998) 698-705
8. Patterson J.E., James M.B., Forster A.H., Lancaster R.W., Butler J.M., and Rades T. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J. Pharm. Sci. 94 9 (2005) 1998-2012
9. Drug Information for Health Care Professional, USP DI, vol. I, 1999.
10. ®N). Int. J. Clin. Pharmacol. Ther. Toxicol. 23 9 (1985) 453-460
11. Blume H., Ali S.L., and Siewert M. Pharmaceutical quality of glibenclamide products: a multinational postmarket comparative study. Drug. Dev. Ind. Pharm. 19 (1993) 2713-2741
12. Panagopoulou-Kaplani A., and Malamataris S. Preparation and characterization of a new insoluble polymorphic form of glibenclamide. Int. J. Pharm. 195 (2000) 239-246
13. ® 80 on the therapeutic efficacy of glibenclamide tablet formulation in terms of BSL lowering in rabbits and diabetic human volunteers. Drug Dev. Ind. Pharm. 12 (1986) 851-866
14. Esclusa-Díaz M.T., Torres-Labandeira J.J., Kata M., and Vila-Jato J.L. Inclusion complexation of glibenclamide with 2-hydroxypropyl-β-cyclodextrin in solution and in solid state. Eur. J. Pharm. Sci. 1 6 (1994) 291-296
15. Valleri M., Mura P., Maestrelli F., Cirri M., and Ballerini R. Development and evaluation of glyburide fast dissolving tablets using solid dispersion technique. Drug Dev. Ind. Pharm. 30 5 (2004) 525-534
16. Tashtoush B., Al-qashi Z.S., and Najib N.M. In vitro and in vivo evaluation of glibenclamide in solid dispersion systems. Drug Dev. Ind. Pharm. 30 6 (2004) 601-607
17. Rupp W., Badian M., Heptner W., and Malerczyk V. Bioavailability and in vitro liberation of glibenclamide from a new dosage form. Biopharm. Pharmacokinet. Eur. Congr. 2 1 (1984) 413-420
18. Hassan M.A., Sheikh Salem M., Sallam E., and Al-Hindawi M.K. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide. Acta Pharmceutica Hungarica 67 2-3 (1997) 81-88
19. Arnqvist H.J., Karlberg B.E., and Melander A. Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes. Ann. Clin. Res. 15 Suppl. 37 (1983) 21-25
20. Timmins P., Marathe P.H., Cave G., Arnold M.E., Dennis A.B., and Greene D.S. Development of a glyburide-metformin fixed combination tablet with optimized glyburide particle size. Drug Dev. Ind. Pharm. 66 (2006) 25-35
21. Wei H., and Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29 (2006) 45-52
22. Personal communication with Dr. Izzy Kanfer, Faculty of Pharmacy, Rhodes University, South Africa.
23. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of in vitro/in vivo Correlations, U.S. Department of Health Food and Drug Administration Center for Drug Evaluation and Research, 1997.
24. Chikhalia V., Forbes R.T., Storey R.A., and Ticehurst M. The effect of crystal morphology and mill type on milling induced crystal disorder. Eur. J. Pharm. Sci. 27 (2006) 19-26
25. Salekigerhardt A., Ahlneck C., and Zografi G. Assessment of disorder in crystalline solids. Int. J. Pharm. 101 3 (1994) 237-247
26. A. Szép, G.Y. Marosi, M. Bálint, A. Bódis, Micro-Raman spectroscopy of solid pharmaceuticals, in: Proceedings of the 8th Polymers for Advanced Technologies International Symposium, vol. 9, Budapest, Hungary, 2005, pp. 13-16.
27. Polymer Science Learning Center, Department of Polymer Science, The University of Southern Mississippi, http://pslc.ws/macrog//dsc.htm
28. Brockmeier D., Grigoleit H.G., and Leonhardt H. Absorption of glibenclamide from different sites of the gastro-intestinal tract. Eur. J. Clin. Pharmacol. 29 2 (1985) 193-197
29. Atkinson R.M., Bedord C., Child K.J., and Tomich E.J. Effect of particle size on blood griseofulvin levels in man. Nature 193 (1962) 588-589
30. Suleiman M.S., and Najib N.M. Isolation and physicochemical characterization of solid forms of glibenclamide. Int. J. Pharm. 50 2 (1989) 103-109
31. Balan G., Timmins P., Greene D.S., and Marathe P.H. In-vitro In-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers. J. Pharm. Pharmacol. 52 (2000) 831-838
32. Rydberg T., Jönsson A., Karlsson M., and Meldander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modeling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 43 (1997) 373-381